|
|
Volumn 25, Issue 9, 2007, Pages 1149-
|
|
Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma? [13]
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
MELPHALAN;
TUMOR NECROSIS FACTOR;
ALKYLATING AGENT;
ANTINEOPLASTIC AGENT;
TUMOR NECROSIS FACTOR ALPHA;
ADJUVANT THERAPY;
CANCER THERAPY;
CLINICAL TRIAL;
CONFIDENCE INTERVAL;
DRUG RESPONSE;
HUMAN;
LETTER;
MELANOMA;
PRIORITY JOURNAL;
STATISTICAL SIGNIFICANCE;
CONTROLLED CLINICAL TRIAL;
HYPERTHERMIC THERAPY;
LIMB;
METASTASIS;
METHODOLOGY;
NOTE;
PATHOLOGY;
RANDOMIZED CONTROLLED TRIAL;
REGIONAL PERFUSION;
STATISTICAL ANALYSIS;
TIME;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC AGENTS, ALKYLATING;
CHEMOTHERAPY, CANCER, REGIONAL PERFUSION;
DATA INTERPRETATION, STATISTICAL;
EXTREMITIES;
HUMANS;
HYPERTHERMIA, INDUCED;
MELANOMA;
MELPHALAN;
RANDOMIZED CONTROLLED TRIALS;
RESEARCH DESIGN;
TIME FACTORS;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 34047214103
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2006.09.4862 Document Type: Letter |
|
Times cited : (4)
|
|
References (2)
|
